發(fā)布時(shí)間：2018-03-17 23:08

  本文選題：生物制藥企業(yè)　切入點(diǎn)：創(chuàng)新資金　出處：《哈爾濱理工大學(xué)》2013年碩士論文　論文類型：學(xué)位論文

【摘要】：創(chuàng)新是生物制藥企業(yè)發(fā)展的關(guān)鍵,而生物制藥企業(yè)創(chuàng)新能力的提高需要獲取大量創(chuàng)新資金的支持,由于企業(yè)不同生命周期對(duì)創(chuàng)新資金的需求不同,所以獲取創(chuàng)新資金的渠道和方式也不同。生物制藥企業(yè)具有高投入、高風(fēng)險(xiǎn)、高收益的特點(diǎn),而創(chuàng)新資金的構(gòu)成及其比例關(guān)系構(gòu)成了企業(yè)創(chuàng)新資金資本結(jié)構(gòu),這就要求對(duì)生物制藥企業(yè)的創(chuàng)新資金資本結(jié)構(gòu)進(jìn)行優(yōu)化,通過資本結(jié)構(gòu)優(yōu)化解決融資問題,對(duì)生物制藥企業(yè)的治理和發(fā)展至關(guān)重要。 本文根據(jù)生物制藥企業(yè)的特點(diǎn)對(duì)不同生命周期創(chuàng)新資金的需求進(jìn)行了分析,并分析了創(chuàng)新資金的融資現(xiàn)狀和資本結(jié)構(gòu)影響因素,由于不同融資方式的融資規(guī)模、融資成本和融資風(fēng)險(xiǎn)等存在差別,對(duì)企業(yè)的創(chuàng)新作用不同,所以本文構(gòu)建融資方式和創(chuàng)新績(jī)效關(guān)系識(shí)別的結(jié)構(gòu)方程模型,為準(zhǔn)確揭示創(chuàng)新資金融資方式與創(chuàng)新績(jī)效的關(guān)系提供方法,有利于生物制藥企業(yè)合理選擇融資方式進(jìn)而提高創(chuàng)新績(jī)效。通過分析融資方式對(duì)創(chuàng)新績(jī)效的影響關(guān)系以及融資方式之間的相互作用關(guān)系,運(yùn)用分形評(píng)價(jià)法確定最優(yōu)資本結(jié)構(gòu),提出針對(duì)性的資本結(jié)構(gòu)優(yōu)化策略,為生物制藥企業(yè)合理確定創(chuàng)新資金資本結(jié)構(gòu)提供依據(jù)。本文的研究有利于提高生物制藥企業(yè)的創(chuàng)新能力和融資水平,對(duì)于優(yōu)化企業(yè)創(chuàng)新資金資本結(jié)構(gòu),提高創(chuàng)新績(jī)效,實(shí)現(xiàn)企業(yè)價(jià)值最大化,促進(jìn)生物制藥企業(yè)可持續(xù)發(fā)展具有重要意義。
[Abstract]:Innovation is the key to the development of biopharmaceutical enterprises, and the improvement of the innovation ability of biopharmaceutical enterprises needs the support of a large number of innovative funds. Therefore, the channels and ways of obtaining innovative funds are also different. Biopharmaceutical enterprises have the characteristics of high input, high risk and high income, and the composition and proportion of innovative funds constitute the capital structure of enterprise innovation funds. This requires the optimization of the innovative capital structure of biopharmaceutical enterprises and the solution of financing problems through the optimization of capital structure, which is of great importance to the governance and development of biopharmaceutical enterprises. According to the characteristics of biopharmaceutical enterprises, this paper analyzes the demand of innovative funds in different life cycles, and analyzes the current financing situation of innovative funds and the influencing factors of capital structure, because of the financing scale of different financing methods. There are differences between financing cost and financing risk, so this paper constructs a structural equation model to identify the relationship between financing mode and innovation performance. In order to accurately reveal the relationship between innovative capital financing and innovation performance, It is helpful for biopharmaceutical enterprises to choose the financing mode reasonably and then improve the innovative performance. By analyzing the influence of the financing mode on the innovation performance and the interaction between the financing methods, the fractal evaluation method is used to determine the optimal capital structure. In order to provide the basis for the biopharmaceutical enterprises to reasonably determine the capital structure of innovative funds, the paper puts forward the targeted capital structure optimization strategy. The research in this paper is conducive to improving the innovation ability and financing level of the biopharmaceutical enterprises. It is of great significance to optimize the capital structure of innovative funds, improve the performance of innovation, maximize the value of enterprises and promote the sustainable development of biopharmaceutical enterprises.
【學(xué)位授予單位】：哈爾濱理工大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2013
【分類號(hào)】：F406.7;F426.72

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 戰(zhàn)明華;許月麗;;公司融資結(jié)構(gòu)調(diào)整、部門異質(zhì)性與中國(guó)信貸渠道的存在性[J];財(cái)經(jīng)研究;2010年12期

2 何琳;廖東聲;;商業(yè)信用的融資成本計(jì)算[J];財(cái)會(huì)月刊;2009年36期

3 楊艷;陳收;;資本成本視角的上市公司融資行為解析[J];系統(tǒng)工程;2008年03期

4 王正位;王思敏;朱武祥;;股票市場(chǎng)融資管制與公司最優(yōu)資本結(jié)構(gòu)[J];管理世界;2011年02期

5 姜付秀;黃繼承;;市場(chǎng)化進(jìn)程與資本結(jié)構(gòu)動(dòng)態(tài)調(diào)整[J];管理世界;2011年03期

6 李天柱;銀路;程躍;;美國(guó)領(lǐng)先生物制藥企業(yè)的成功要素及其啟示[J];管理學(xué)報(bào);2010年09期

7 王玉冬;何曉燕;;高新技術(shù)企業(yè)資本結(jié)構(gòu)優(yōu)化研究[J];哈爾濱理工大學(xué)學(xué)報(bào);2009年01期

8 李哲峰;;中國(guó)中小企業(yè)融資現(xiàn)狀及原因分析[J];經(jīng)濟(jì)研究導(dǎo)刊;2011年22期

9 王躍堂;王亮亮;彭洋;;產(chǎn)權(quán)性質(zhì)、債務(wù)稅盾與資本結(jié)構(gòu)[J];經(jīng)濟(jì)研究;2010年09期

10 李喜梅;;中國(guó)農(nóng)村經(jīng)濟(jì)發(fā)展水平的分形評(píng)價(jià)[J];經(jīng)濟(jì)縱橫;2008年12期

，

本文編號(hào)：1626897